Literature DB >> 25520046

A proposal of postoperative follow-up pathways for lung cancer.

Shigeki Sawada1, Satoshi Shiono, Yoshinori Yamashita, Tsutomu Tagawa, Hiroyuki Ito, Toshihiko Sato, Hiroaki Harada, Motohiro Yamashita.   

Abstract

OBJECTIVES: Although follow-up surveillance after resection for lung cancer is commonly performed in clinical practice, there is no standard follow-up program. We attempted to establish follow-up examination schedules that we considered would be acceptable to the majority of doctors, and would like to propose them as standard postoperative follow-up pathways.
METHODS: We carried out a retrospective analysis of patients' data and reviewed the time of detection of recurrence and the site of recurrence after resection. Published papers were also reviewed. The postoperative follow-up pathways were established based on these data. PROPOSED FOLLOW-UP PATHWAY: The follow-up period was set at as 5 years after resection, and physical examinations, chest radiography, chest CT and blood examination are recommended. Two follow-up pathways were proposed taking the risk of recurrence into consideration: the Risk of recurrence-based pathway and the Comprehensive pathway. In the Risk of recurrence-based pathway, the follow-up examination schedule is modified according to the risk of recurrence. In the Comprehensive pathway, a single universal examination schedule is recommended for all patients. The choice between these two pathways is left to the discretion of the attending doctor.
CONCLUSIONS: We proposed two follow-up pathways, based on retrospective analysis of patients' data and a review of published papers, which we considered would be acceptable to the majority of doctors and would be suited to the current medical environment in Japan. A prospective study to evaluate the efficacy of the follow-up pathways is ongoing.

Entities:  

Mesh:

Year:  2014        PMID: 25520046     DOI: 10.1007/s11748-014-0506-7

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  36 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Current status of postoperative follow-up for lung cancer in Japan: questionnaire survey by the Setouchi Lung Cancer Study Group-A0901.

Authors:  Shigeki Sawada; Hiroshi Suehisa; Motohiro Yamashita; Masao Nakata; Norihito Okumura; Kazunori Okabe; Hiroshige Nakamura; Hirohito Tada; Shinichi Toyooka; Hiroshi Date
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-02-12

3.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

4.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).

Authors:  E Felip; R A Stahel; N Pavlidis
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

5.  Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

6.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

7.  Cost of patient follow-up after potentially curative lung cancer treatment.

Authors:  K S Virgo; K S Naunheim; L W McKirgan; M E Kissling; J C Lin; F E Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

8.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).

Authors:  Jeffrey Rubins; Michael Unger; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

9.  Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Authors:  Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease.

Authors:  Morihito Okada; Wataru Nishio; Toshihiko Sakamoto; Kazuya Uchino; Tsuyoshi Yuki; Akio Nakagawa; Noriaki Tsubota
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.